Esperion Therapeutics, Inc.

As of October 3, 2025, the trend is mildly bullish, supported by a bullish MACD and moving average, but mixed signals from the RSI and KST suggest a cautious outlook.

As of October 3, 2025, Esperion Therapeutics, Inc. shows a mildly bullish trend with mixed indicators, including bullish weekly MACD and Bollinger Bands, but a bearish weekly RSI suggesting potential short-term weakness.

As of October 3, 2025, Esperion Therapeutics, Inc. shows a mildly bullish technical trend, supported by strong short-term indicators, despite mixed signals in the longer term and recent outperformance against the S&P 500.

As of September 19, 2025, Esperion Therapeutics, Inc. shows a bullish technical trend with strong recent performance, returning 15.67% over the past month and 49.40% over the past year, despite long-term underperformance over 3 and 5 years.

As of September 19, 2025, Esperion Therapeutics, Inc. is in a bullish trend with strong indicators, having returned 30.39% over the past month and 52.00% over the past year, although it has underperformed the S&P 500 over the longer term.

As of September 8, 2025, Esperion Therapeutics, Inc. shows a bullish trend supported by positive indicators, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with returns of 30.95% over the past month and 58.05% over the past year.

As of May 8, 2019, Esperion Therapeutics, Inc. is considered overvalued with a risky valuation grade due to negative financial metrics and a concerning long-term performance, despite a recent short-term stock gain.

As of May 8, 2019, Esperion Therapeutics, Inc. is considered "risky" and overvalued due to poor financial metrics, including a Price to Book Value of -0.57 and significant underperformance against peers and the S&P 500, with a year-to-date return of -52.73%.

As of June 3, 2025, Esperion Therapeutics, Inc. is in a mildly bearish trend, influenced by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from weekly MACD and KST.

As of March 2022, the management team of Esperion Therapeutics, Inc. includes Timothy Mayleben as President and CEO, with Nicole Vitullo as Lead Independent Director. The Board of Directors features independent members Jeffrey Berkowitz, Alan Fuhrman, Antonio Gotto, and Daniel Janney.

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing oral therapies for managing elevated LDL cholesterol. As of March 2025, it reported net sales of $65 million and a net loss of $40 million, with a market cap of $218.21 million.

As of Jun 18, Esperion Therapeutics, Inc. has a market capitalization of 218.21 million and reported net sales of 259.57 million with a net profit of -153.21 million over the latest four quarters. Shareholder's funds are -388.72 million, and total assets are 345.34 million.